E. Anders Kolb
President & CEO
The Leukemia and Lymphoma Society (LLS)
2024-11-28
Two key areas require our focus: advancing discovery and improving access to care. On the discovery front, we must invest in cutting-edge research and push for breakthroughs in therapies for diseases like AML and multiple myeloma, where survival rates have lagged. Transformational discoveries, akin to CAR T-cell therapies or menin inhibitors, are crucial for these more refractory cancers.